Group 1 - The eighth Hainan International Health Industry Expo and the China International Biopharmaceutical Conference focused on cross-border pharmaceutical and medical device cooperation, highlighting the role of Hainan's free trade port policy in promoting Chinese pharmaceuticals globally [2] - The forum addressed the challenges patients face in finding and purchasing medications, with companies like Yididi providing one-stop pharmaceutical services and a rapid response system to meet domestic patients' needs within 72 hours [2][3] - Medikabazaar (China) focuses on serving emerging markets in China and Southeast Asia by offering high-quality, compliant generic drugs and streamlining the supply chain from overseas procurement to domestic customs clearance [2][3] Group 2 - The medical device industry in India is experiencing rapid growth, with significant demand for high-quality, cost-effective medical devices from China, presenting notable overseas market opportunities [3] - Companies face challenges in the medical device export process, including registration, team building, promotion, and after-sales maintenance, necessitating localized operations and a strong execution team [3] - Under the Hainan free trade port policy, Yididi is expanding its global operations, having already initiated localized operations in Southeast Asia and Japan, and is exploring pathways for traditional Chinese medicine to enter the Thai market [3]

Investment Rating - The industry investment rating is "Outperform the Market" (预计6个月内，行业指数表现强于市场表现5%以上) [32] Core Insights - The National Healthcare Security Administration issued the "Guidelines for the Establishment of Pricing Projects for Pathological Medical Services (Trial)," which aims to systematically reshape existing pathological pricing projects, focusing on biopsy sampling, sample processing, slice replication, pathological staining, and diagnosis, establishing 28 pricing projects, 3 additional charges, and 2 expansion items. This refined pricing is expected to promote high-quality development in pathology and create new scenarios for the application of artificial intelligence-assisted technologies [4] - The guidelines will standardize the charging for digital pathological slices, solidifying the data foundation for large-scale applications of new scenarios. It includes "providing digital images of pathological slices" as an essential item for various pathological services, reflecting the costs of related resource consumption in pricing [4] - The guidelines also explore suitable forms to respond to the charging demands of artificial intelligence assistance, promoting the early application of AI in the pathology field by including "AI-assisted diagnosis" as an expansion item in the pricing structure [4] - The establishment of separate pricing projects for pathological diagnosis and sample testing emphasizes the value of technical services and supports precise medication guidance [4] Summary by Sections Investment Strategy - The report suggests focusing on innovative pharmaceutical companies with rich pipeline layouts, such as Heng Rui Medicine, BeiGene, and China National Pharmaceutical Group. It also highlights companies with significant single-product potential and price revaluation prospects, such as 3SBio, Kaineng Technology, and Qianhong Pharmaceutical. Additionally, it recommends companies leading in cutting-edge technology platform layouts, such as Dongcheng Pharmaceutical, Yuanda Pharmaceutical, and Kelun-Biotech [6] - In the CXO sector, it notes that R&D investment in pharmaceuticals is steadily increasing, and the innovation environment is expected to improve, suggesting attention to companies like WuXi AppTec, WuXi Biologics, and Boteng Co. [6] - For upstream companies, it indicates that quality enterprises are entering a harvest period with overseas layouts, recommending attention to Aopumai, Baipusais, and Baiyao [6] - In the medical device sector, it mentions that ongoing procurement will continue to advance, with equipment companies gradually digesting channel inventory, suggesting attention to Mindray Medical, United Imaging, and Kaili Medical [6] Industry News - The report highlights several key developments in the industry, including Takeda's TYK2 drug achieving positive results in Phase III studies, Baiyatai's anti-VEGF monoclonal antibody application for market approval, Sanofi's innovative therapy for hypertrophic cardiomyopathy receiving domestic approval, and Enhertu (Trastuzumab Deruxtecan) gaining FDA approval for a new indication [8][12][15][16]

Group 1 - The company reported a revenue of 7.72 billion yuan in the first half of 2025, with the liquid rocket engine thrust chamber business generating 23.29 million yuan [1] - Revenue from the liquid rocket engine thrust chamber products is projected to grow from 20.97 million yuan in 2022 to 30.16 million yuan in 2024, maintaining rapid growth into 2025 [1] - The company has initiated a project for the industrialization of materials, parts, and components for liquid rocket engine thrust chambers, with an initial investment of 230 million yuan aimed at achieving an annual production capacity of approximately 200 tons of forgings and various rocket engine components [1] Group 2 - In the high-end medical equipment core components sector, the company holds a significant position in the CT and DR tube components market in China [2] - The company primarily provides products and technical services to domestic CT tube manufacturers while also expanding into international markets [2] - Major clients include Siemens Healthineers, United Imaging, Kunshan Medical Source, and others, with the company becoming a strategic supplier for some of these clients [2]

Group 1 - The 2025 Hainan International Health Industry Expo (Hainan Health Expo) has generated significant interest, with long queues at the consultation and free medical check-up areas, indicating a high level of engagement from attendees [1] - Various exhibitors showcased a wide range of health products and services, enhancing the interactive experience for visitors, which is expected to provide convenience for those in need [1] - The event featured a nutrition knowledge competition organized by exhibitors in the dietary and brand exhibition area, aimed at promoting the concept of "the fourth meal of Chinese residents" and educating attendees on the value of nutrition [1] Group 2 - The expo attracted key domestic parks such as the Boao Lecheng International Medical Tourism Pilot Zone and Sanya Yazhou Bay Science and Technology City, highlighting the collaboration among different regions to promote health and wellness products [2] - The event emphasized advanced medical devices and "black technology" in the medical equipment industry, showcasing high-tech innovations like interventional robots and smart wearable devices from companies such as United Imaging and Huawei [2]

浙商证券指出，自2024年9月24日以来，本轮AI主线引领的大行情中，科创板是引领板块。类似于，2013年至2015年互联网主线引领的大行情中，创业 板是引领板块。今年以来，特别是6月以来，科创板系列指数涨幅居前。 今日（12.19），A股震荡走高，全市场费率最低档的科创50指数ETF（588870）收涨0.23%，全天成交额超3300万元。资金借道ETF布局，科创50指数 ETF（588870）近5日有3日获净流入！截至12月18日，科创50指数ETF（588870）年内份额增长率高达170%，同类断层领先！ | 序号 | 代码 | 名称 | 估算权重 ▼ | 涨跌幅 | 成交额 | | --- | --- | --- | --- | --- | --- | | 1 | 688981 | 中古国际 | 9.87% | 0.74% | 31.07亿 | | 2 | 688256 | 寒武纪-U | 9.65% | -1.48% | 55.27 亿 | | 3 | 688041 | 海光信息 | 8.11% | 0.68% | 37.87亿 | | 4 | 688008 | 澜起科技 | 5.84% | 0.6 ...

10% 医药生物 沪深300 医药生物行业 -5% 0% 5% 10% 医药生物 沪深300 超配（维持） 医药生物行业双周报（2025/12/5-2025/12/18） 29 省耗材联盟集采启动 投资要点： 本报告的风险等级为中高风险。 本报告的信息均来自已公开信息，关于信息的准确性与完整性，建议投资者谨慎判断，据此入市，风险自担。 请务必阅读末页声明。 行 业 研 医药生物（申万）指数走势 -35% 资料来源：iFind，东莞证券研究所 -40% -20% 0% 20% 22-03 22-05 22-07 22-09 22-11 23-01 23-03 相关报告 -30% -25% -20% -15% -10% -5% 0% 5% 10% 医药生物 沪深300 -35% -30% -25% -20% -15% -10% 5% -35% -30% -25% -20% -15% -10% -5% 0% 医药生物 沪深300 -35% -30% -25% -20% -15% -10% -5% 0% 5% 10% 医药生物 沪深300 2025 年 12 月 19 日 分析师：谢雄雄 SAC 执业证书编号： S0 ...

Core Viewpoint - Interventional radiology navigation systems enhance the precision and safety of minimally invasive procedures by integrating medical imaging, sensing technology, spatial positioning algorithms, and surgical path planning, transitioning from experience-driven to data-driven operations [2][5]. Working Principle - The system operates through three main technical modules: image acquisition, coordinate matching, and real-time tracking. It creates a 3D model of the lesion and surrounding tissues using CT, MRI, or ultrasound images, matches the patient's anatomy with the model, and tracks instruments in real-time to provide accurate navigation [4]. Application Areas - Interventional radiology navigation systems are widely used in tumor ablation, biopsy, vascular interventions, and complex anatomical region treatments. They improve accuracy in procedures like liver tumor ablation and vascular interventions by providing real-time corrections and reducing reliance on contrast agents [5]. Development Prospects - The future of interventional radiology navigation systems is geared towards higher precision, intelligence, and automation, driven by advancements in AI, robotics, and multimodal imaging. These technologies aim to enhance clinical success rates and optimize treatment pathways [6]. Important Parameters - Key parameters include spatial positioning accuracy (0.5–1.0mm for high-end systems), tracking stability, navigation modes (electromagnetic, optical), and image processing capabilities, which are crucial for effective navigation [7][8]. Market Size - The interventional radiology navigation system market is projected to reach USD 479 million in 2024 and USD 507 million in 2025, with a compound annual growth rate (CAGR) of 6.3% over the next six years [10]. Industry Chain and Trends - The industry chain shows a clear upstream and downstream collaboration, with upstream relying on precision sensors and imaging devices, while downstream includes medical institutions that adopt these systems to enhance procedural accuracy and reduce complications [14]. The industry is experiencing a trend towards digitalization, intelligence, and automation, with increasing demand for high-precision navigation [16]. Entry Barriers - High entry barriers exist due to the technical complexity of navigation systems, stringent certification requirements, and the strong market presence of established brands. New entrants must invest significantly in training and support to compete effectively [17].

Group 1: Pharmaceutical Sector - The innovation drug sector is expected to be the main focus, with particular attention on small nucleic acid technology and its accelerated development by 2026 [1][2] - The pharmaceutical industry is driven by supply creating demand, with significant trends observed from 2018 to 2024, including breakthroughs in PD-1, ADC technology, and new generation immunotherapy [2] - Key companies to watch in the pharmaceutical sector include Heng Rui Medicine, Hansoh Pharmaceutical, China National Pharmaceutical Group, and others involved in small nucleic acid and weight loss drug development [2] Group 2: CXO and Upstream Life Sciences - The CXO sector is expected to see continued improvement in fundamentals and valuation recovery, with a focus on companies like WuXi AppTec and Kanglong Chemical [3] - Upstream life sciences are benefiting from improved domestic research conditions, with companies like BGI Genomics and Bidu Pharmaceutical showing positive performance trends [3] - The raw material drug sector is entering a bottom price range, with companies that have quality clients and orders likely to see improved profit margins [3] Group 3: Medical Devices - The medical device sector is anticipated to benefit from improved hospital demand and inventory optimization, with a potential turning point in 2026 [4] - High-value consumables are expected to gain from collective procurement, enhancing domestic production capabilities [4] - Key players in the medical device sector include Mindray Medical, United Imaging Healthcare, and others [4] Group 4: Healthcare Consumption - The healthcare service sector is under pressure in 2025, but a mild recovery is expected in 2026, particularly in essential medical services and products [5] - Traditional Chinese medicine is projected to stabilize and grow, with a focus on OTC and prescription drug innovations [5] - The pharmacy sector is experiencing increased concentration due to regulatory changes, with companies like Yifeng Pharmacy and Dazhong Pharmacy showing improved performance [5]

Group 1 - The Wuhan Investment Promotion Conference announced the signing of 160 industrial projects with a total investment of 110.97 billion yuan, covering various sectors including artificial intelligence, new generation information technology, health and biomanufacturing, digital economy, optoelectronic information, smart connected vehicles, new energy, new materials, and high-end equipment manufacturing [1] - Wuhan is in a critical period of urban capability enhancement, advantage transformation, and regional collaboration, aiming to share new development opportunities with entrepreneurs and support their growth in the city [1] - The city is implementing a gradient cultivation plan for technology-based enterprises and enhancing inbound consumption attractiveness through increased tax refund store layouts [1] Group 2 - Companies are increasing investments in Wuhan, with Union Medical Group planning to focus further investments in the East Lake High-tech Zone to build a global high-end medical equipment innovation manufacturing base [2] - Union Medical Group aims to achieve breakthroughs in AI medical technology and medical robotics, and plans to establish a research and manufacturing center in Wuhan employing thousands [2] - Ampofo Electric's new project in Wuhan Economic Development Zone will focus on electric vehicle chargers and high-voltage connectors, with an expected production start in the second half of 2026 [2] Group 3 - The newly established Zero One Wanwu AI Industry Base in Wuhan aims to create a nationally influential AI city, leveraging solid computing power and diverse application scenarios [3] - The base will establish a vibrant ecosystem for AI algorithms, data, and talent cultivation, supporting the regional development of the AI industry [3]

Core Viewpoint - Srey New Materials holds a significant position in the domestic CT and DR tube component market, providing products and technical services primarily to domestic CT tube manufacturers while also expanding into international markets [1] Group 1: Company Positioning - The company is one of the few in China capable of offering these products and "one-stop" technical services [1] - Major clients include Siemens Healthineers, United Imaging Healthcare, Kunshan Medical Source, Maimo Vacuum, Deke Ruisi, and Beijing Zhisu, with some clients being strategic cooperative suppliers [1] Group 2: Market Strategy - Srey New Materials is actively exploring international markets to enhance its business reach [1]